Recent developments
Regulatory and quality
WuXi Biologics secured MHRA GMP certification for commercial ophthalmic biologic manufacturing at DP5 and DPPC following a four‑day inspection without critical findings. Separately, three Wuxi facilities gained GMP certification from Türkiye’s TITCK, reinforcing multi‑site compliance for monoclonal antibody and drug product operations.
Digital bioprocessing
WuXi Biologics launched the PatroLab digital twin platform, integrating Raman PAT, real‑time monitoring of 40+ attributes, and hybrid mechanistic/data models to enable model‑predictive control, QbD implementation, and alignment with FDA/EMA guidance for real‑time release testing.
ESG and procurement
WuXi achieved ISO 20400 sustainable procurement certification and earned CDP “A” ratings for climate and water. The company maintained an MSCI AAA ESG rating and gained Hang Seng Corporate Sustainability Benchmark Index inclusion, signaling continued emphasis on supply‑chain transparency and resource efficiency.
Capacity and footprint
WuXi moved to expand its CRDMO network to Qatar via an MoU with QFZ for complex biologics. Terumo completed the acquisition of a Leverkusen drug product plant from WuXi, adding EU fill‑finish capacity. Merck advanced U.S. manufacturing with the construction of a $3 billion facility in Virginia. BBG and CELLforCURE formed a transatlantic ATMP manufacturing partnership.
Supply chain and inputs
Brenntag and Seqens entered a sole distribution partnership for non‑GMP intermediates in Europe. Croda and Amino announced a strategic supply partnership to launch BioXPro high‑purity amino acids for biomanufacturing.
Drug delivery and excipients
Evonik introduced GMP‑grade EUDRACAP colon capsules at CPHI Frankfurt; subsequently, EUDRACAP colon won the CPHI Excellence in Pharma Award. The company also launched MaxiPure Polysorbate 80 for injectable applications to improve stability and consistency in sensitive formulations.
Modalities and processing tech
Evonik and Ethris formed a strategic collaboration on a lipid nanoparticle platform for nucleic acid delivery. MGC and Cirena outlined exclusive distribution plans for long‑chain RNA in Japan. Evonik launched Noblyst F catalysts for flow applications, supporting continuous processing in pharma and fine chemicals.
Innovation ecosystems
Lilly announced a new Lilly Gateway Labs site in Philadelphia to support early‑stage biotech. A separate Lilly–IU agreement to expand clinical trial access targets AI‑enabled infrastructure, potentially accelerating development programs and downstream CDMO demand.